CCA
NUVB icon

Cygnus Capital Advisors’s Nuvation Bio NUVB Stock Holding History

Cygnus Capital Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17 Hold
3,872
– – 0.01% 90
2025
Q4 		$35 Buy
+3,872
New +$24K 0.03% 70

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cygnus Capital Advisors's NUVB Position: Q1 2026 in Review

Cygnus Capital Advisors held its Nuvation Bio (NUVB) position steady in Q1 2026 at 3,872 shares worth $17. The position accounts for 0.01% of the portfolio, ranked #90.

Cygnus Capital Advisors first reported a position in NUVB in Q4 2025 and has held it in 2 quarters since. The position peaked at $35 in Q4 2025. 233 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Cygnus Capital Advisors held 3,872 shares of Nuvation Bio worth $17 as of Q1 2026.
  • Cygnus Capital Advisors left its Nuvation Bio share count unchanged in Q1 2026.
  • Nuvation Bio made up 0.01% of Cygnus Capital Advisors's portfolio in Q1 2026, its #90 holding.
  • Cygnus Capital Advisors first reported a position in Nuvation Bio in Q4 2025 and has held it in 2 quarters since.
  • Cygnus Capital Advisors's Nuvation Bio position peaked at $35 in Q4 2025.
  • 233 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.